The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Takeaways From TransATAC Trial on Comparing Prognostic Signatures

William J. Gradishar, MD
Published Online: 11:48 PM, Fri December 9, 2016

William J. Gradishar, MD, deputy director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine, discusses the takeaways from the TransATAC trial, which was a comprehensive comparison of prognostic signatures in breast cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.